Regeneron (NASDAQ: REGN) entered an agreement to acquire 23andMe for $256 million, which is a tiny fraction of its previous ...

Regeneron, a biotech company, will acquire 23andMe for $256 million and vowed to comply with the genetic testing company's ...

Regeneron Pharmaceuticals said it will acquire 23andMe's business. What happened to 23andMe? Should you delete your data?

The proposed transaction with Regeneron includes 23andMe’s personal genome service and total health and research services.

Biotechnology company Regeneron will acquire 23andMe out of bankruptcy for $256 million, with a plan to keep the DNA-testing ...

The sale was for $256 million and is expected to be complete by the third quarter of this year, according to a Regeneron news ...

Regeneron Pharmaceuticals on Monday said it would buy genetic testing company 23andMe, which filed for bankruptcy in March following a series of setbacks.

Regeneron is acquiring “substantially all” of 23andMe’s assets for $256 million following a bankruptcy auction.

Genetic testing company 23andMe filed for bankruptcy in March. Regeneron Pharmaceuticals on Monday announced plans to purchase genetic testing company 23andMe for $256 million. The New York-based ...

Genetic testing company 23andMe filed for Chapter 11 bankruptcy protection in March. Regeneron Pharmaceuticals announced it would buy "substantially all" of 23andMe's assets.